Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.44 |
| ▸ | RARB | P10826 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15177162 | 0.80 | MAPT (0.43) | L3MBTL1MMP1PLA2G4BRARBTP53 | |
| SCHEMBL4556801 | 0.78 | TSHR (0.51) | L3MBTL1MMP1PLA2G4BTP53TSHR | |
| SCHEMBL31111454 | 0.77 | CYSLTR2 (0.45) | PLA2G4BRARBTHRATHRBALDH1A1 | |
| SCHEMBL4556519 | 0.75 | LTA4H (0.50) | L3MBTL1ALDH1A1NPC1 | |
| SCHEMBL4549099 | 0.75 | MAPK1 (0.52) | L3MBTL1PLA2G4BALDH1A1NPC1 | |
| SCHEMBL12947237 | 0.73 | MAPT (0.46) | L3MBTL1PLA2G4BALDH1A1NPC1 | |
| SCHEMBL13303326 | 0.72 | LTA4H (0.55) | — | |
| SCHEMBL18917595 | 0.72 | L3MBTL1 (0.63) | L3MBTL1MMP1PLA2G4BRARBTP53 | |
| SCHEMBL9504211 | 0.70 | RARB (0.82) | PLA2G4BRARBTP53TSHR | |
| SCHEMBL7631505 | 0.70 | MMP1 (0.57) | L3MBTL1MMP1PLA2G4BTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507549-B2 | Methods for synthesizing glycinols, glyceollins I and II and isoflavenes and chromanes using a Wittig reaction, and compositions made therewith | THE UNIVERSITY OF TOLEDO (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | THE UNIVERSITY OF TOLEDO | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | UGGT1, GCG, UGT8 | L3MBTL1 4827/4885MMP1 2939/4885PLA2G4B 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.